Annexon Biosciences, Inc. (ANNX)
NASDAQ:ANNX
Want to see ANNX full AI Analyst Report?
Total Valuation
Annexon Biosciences has a market cap or net worth of $825.77M. The enterprise value is $452.99M.
Market Cap$825.77M
Enterprise Value$452.99M
Share Statistics
Annexon Biosciences has 163,842,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding163,842,540
Owned by Insiders6.72%
Owned by Institutions42.32%
Financial Efficiency
Annexon Biosciences’s return on equity (ROE) is -0.98 and return on invested capital (ROIC) is -90.99%.
Return on Equity (ROE)-0.98
Return on Assets (ROA)-0.74
Return on Invested Capital (ROIC)-90.99%
Return on Capital Employed (ROCE)-0.92
Revenue Per Employee0.00
Profits Per Employee-1.95M
Employee Count106
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Annexon Biosciences is ―. Annexon Biosciences’s PEG ratio is -0.12.
PE Ratio―
PS Ratio0.00
PB Ratio3.68
Price to Fair Value3.68
Price to FCF-4.18
Price to Operating Cash Flow-5.35
PEG Ratio-0.12
Income Statement
In the last 12 months, Annexon Biosciences had revenue of 0.00 and earned -206.69M in profits. Earnings per share was -1.34.
Revenue0.00
Gross Profit-3.69M
Operating Income-216.41M
Pretax Income-206.69M
Net Income-206.69M
EBITDA-213.76M
Earnings Per Share (EPS)-1.34
Cash Flow
In the last 12 months, operating cash flow was -183.10M and capital expenditures -63.00K, giving a free cash flow of -183.16M billion.
Operating Cash Flow-183.10M
Free Cash Flow-183.16M
Free Cash Flow per Share-1.12
Dividends & Yields
Annexon Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.63
52-Week Price Change155.84%
50-Day Moving Average5.67
200-Day Moving Average4.44
Relative Strength Index (RSI)35.17
Average Volume (3m)2.12M
Important Dates
Annexon Biosciences upcoming earnings date is Aug 17, 2026, TBA (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Annexon Biosciences as a current ratio of 5.68, with Debt / Equity ratio of 12.44%
Current Ratio5.68
Quick Ratio5.68
Debt to Market Cap0.00
Net Debt to EBITDA0.64
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Annexon Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Annexon Biosciences EV to EBITDA ratio is -3.01, with an EV/FCF ratio of -3.45.
EV to Sales0.00
EV to EBITDA-3.01
EV to Free Cash Flow-3.45
EV to Operating Cash Flow-3.45
Balance Sheet
Annexon Biosciences has $225.03M in cash and marketable securities with $25.43M in debt, giving a net cash position of $199.59M billion.
Cash & Marketable Securities$225.03M
Total Debt$25.43M
Net Cash$199.59M
Net Cash Per Share$1.22
Tangible Book Value Per Share$1.36
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Annexon Biosciences is $14.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$14.00
Price Target Upside114.07% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast-3.74%